1 to 9 of 17 results

Pipeline innovation bodes well for systemic lupus erythematosus market


While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

EU5 rheumatologits rate Rituxan and Benlysta for Lupus


Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Epratuzumab and Lupuzor have potential to offer improvements over Benlysta in reducing Lupus disease activity


US and European rheumatologists surveyed by health care advisory firm Decision Resources indicate that…

Anthera PharmaceuticalsAnti-Arthritics/RheumaticsBenlystaBiotechnologyblisibimodepratuzumabEuropeGlaxoSmithKlineImmunomedicsImmuPharmaLupuzorMarkets & MarketingNorth AmericaPharmaceuticalUCB

UK NICE agrees to reconsider decision to deny NHS access to GSK's Benlysta


The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) confirmed this…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlinePharmaceuticalPricingRare diseasesRegulation

Benlysta continues to penetrate lupus market one year post-launch; report


More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceuticalRare diseases

UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin


There was a batch of bad news emanating from the US drugs watchdog the National Institute for Health…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRare diseasesRegulationRocheTyverb

Thought leaders indicate Benlysta has advantages over market leader CellCept for Lupus


Surveyed US rheumatologists and managed care organization (MCO) pharmacy directors agree that reducing…

Anti-Arthritics/RheumaticsBenlystaCellCeptEli LillyforigerimodGlaxoSmithKlineHuman Genome SciencesImmuPharmaMarkets & MarketingNorth AmericaPharmaceuticalRare diseasesRocheSymBio Pharmaceuticalstabalumab

Benlysta gaining bigger US market share


Over half of surveyed US rheumatologists surveyed by Decision Resources unit BioTrends have initiated…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingNorth AmericaPharmaceuticalRare diseases

1 to 9 of 17 results

Back to top